Wealth Enhancement Advisory Services
VRCA icon

Wealth Enhancement Advisory Services’s Verrica Pharmaceuticals VRCA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,157
Closed -$8.17K – 3711
2025
Q2 		$8.17K Sell
1,157
-30
-3% -$161 ﹤0.01% 3371
2025
Q1 		$5.25K Buy
1,187
+174
+17% +$1.13K ﹤0.01% 2966
2024
Q4 		$7.09K Buy
+1,013
New +$11.1K ﹤0.01% 2935

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Wealth Enhancement Advisory Services's VRCA Position: Q3 2025 in Review

Wealth Enhancement Advisory Services sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 1,157 shares — an estimated $8.17K sold.

Wealth Enhancement Advisory Services first reported a position in VRCA in Q4 2024 and held it in 3 quarters. The position peaked at $8.17K in Q2 2025. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Wealth Enhancement Advisory Services reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 1,157 Verrica Pharmaceuticals shares in Q3 2025, an estimated $8.17K.
  • Wealth Enhancement Advisory Services first reported a position in Verrica Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Wealth Enhancement Advisory Services's Verrica Pharmaceuticals position peaked at $8.17K in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2025, filed 29 Oct 2025.